DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

BROSSARD, Quebec, March 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the terms of an aggregate amount of $510,000 of unsecured convertible debentures (each, a Debenture) issued as part of a non-brokered private placement of units initially announced on March 1, 2022, and subsequently amended on March 1, 2025 (pleaser refer to the press release dated February 28, 2025). The amendments are as follows:

DIAGNOS, a company known for its advancements in artificial intelligence, announced significant amendments to its convertible debentures and stock warrants on March 5, 2026. This announcement marks a strategic move for the company as it aims to enhance its financial structure and leverage investment opportunities.

The amendments included changes to the terms of the convertible debentures, which are instruments that allow investors to convert their debt into equity at predetermined rates. By adjusting these terms, DIAGNOS is not only providing flexibility to its investors but is also positioning itself to secure essential funding for future projects and expansions in the competitive landscape of healthcare technology.

Additionally, the company also made revisions to its stock warrants. Stock warrants give holders the right to purchase shares of the company at a specified price within a certain timeframe. The changes are expected to incentivize potential investors and foster a more robust investment climate around DIAGNOS, allowing the company to attract capital and strengthen its balance sheet.

This strategic move arrives at a pivotal moment in the company's growth trajectory, especially considering the evolving demands in the fields such as diagnostics and AI technology. By addressing the terms of its financial instruments, DIAGNOS is signaling its commitment to transparency and adaptability, which are crucial in maintaining investor confidence and fostering long-term partnerships.

Moreover, the adjustments to the convertible debentures and stock warrants could lead to enhanced market access and could represent a crucial step toward increased operational capabilities and innovative solutions delivery in the diagnostic sector. This could have significant implications for the company’s future, especially as it relates to innovation and competitiveness in a market that is consistently seeking more efficient and effective diagnostic solutions.

The company’s announcement has garnered attention from stakeholders and analysts alike. Many view these amendments as a positive step towards providing more value to existing shareholders while creating new opportunities for investors looking to enter the market. Overall, this strategic amendment signifies DIAGNOS's proactive approach to navigating challenges and maximizing growth potential as it continues to evolve within a rapidly changing industry.